The average comprises six short-term price targets ranging from a low of $19 to a high of $60.06, with a standard deviation of $17.78. While the lowest estimate indicates an increase of 50.2% from the current price level, the most optimistic estimate points to a 374.8% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 (919) 314-5512 (Registrant's telephone number, including area code) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38841 Precision BioSciences, Inc. (Exact Name of ...

Exhibit 99.1 Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update DURHAM, N.C., May 13, 2024 -- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update. "In 2024, Precision ...

After reaching an important support level, Precision BioSciences, Inc. (DTIL) could be a good stock pick from a technical perspective. DTIL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer- ...

分组1 - Precision BioSciences (DTIL) 过去四周股价上涨23%，收盘价为$15.37，根据华尔街分析师的短期价格目标，股票仍有潜在上涨空间[1] - 分析师的平均估值为$78.07，表示潜在上涨407.9%，其中最低估值为$30.03，最高估值为$150.15，标准偏差为$45.55[2] 分组2 - 仅仅依靠共识价格目标来做投资决策可能不明智，因为分析师设置价格目标的能力和公正性一直存在质疑[3] - DTIL强劲的平均价格目标并不是潜在上涨的唯一指标，分析师对公司能够报告比他们之前预测的更好的收益能力的强烈一致性也支持了这一观点[4]

Precision BioSciences (DTIL)股价表现 - Precision BioSciences (DTIL)股价在最近一个交易日上涨了13.4%，收于15.37美元[1] - 公司宣布2023年第四季度和全年的财务业绩强劲，可能推动了股价上涨[2] - 预计这家基因组编辑公司将在即将发布的报告中每股亏损1.80美元，同比增长74%，预计营收为1050万美元，同比增长19.6%[3] - 股价通常不会在没有盈利预期修订趋势的情况下持续上涨，因此需要密切关注DTIL的未来走势[5] - Precision BioSciences目前持有Zacks Rank 3（持有）[6] ChromaDex (CDXC)的财务表现 - ChromaDex（CDXC）的共识每股收益预期在过去一个月内变化了-200%，为-0.03美元，与一年前相比没有变化，目前持有Zacks Rank 3（持有）[7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38841 Precision BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-4206017 (State or other jurisdic ...

PBGENE-PMM项目介绍 - Precision BioSciences公司利用其ARCUS®平台开发PBGENE-PMM项目，旨在治疗m.3243相关的原发性线粒体肌病(PMM) [1] - ARCUS能够精确编辑线粒体DNA，消除突变线粒体DNA，保留正常功能的野生型线粒体DNA，从而改善线粒体功能 [2] - PBGENE-PMM在细胞中成功实现m.3243A>G杂合体内突变线粒体DNA的显著减少，进而提高基础和最大呼吸率 [3]

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has received approval from the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) for the company’s Clinical Trial Authorization (CTA) application to expand the Phase 1/2 OTC-HOPE ...

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today approval from the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) of the company’s Clinical Trial Authorisation application (CTA) to expand the OTC-HOPE study into the U.K. The OTC-HOPE study is investigating ECUR-506, an investigational gene ed ...